Enterprise Value
1.648B
Cash
121.5M
Avg Qtr Burn
N/A
Short % of Float
12.06%
Insider Ownership
1.70%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Linzess® (linaclotide) Details Constipation | Approved Quarterly sales | |
Linzess® (linaclotide) Details Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder | Approved Quarterly sales | |
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome | Phase 3 Update | |
Apraglutide (agonist of the GLP-2 receptor) Details Acute graft-versus host disease | Phase 2 Data readout | |
IW-3300 Details Endometriosis, Visceral pain, Interstitial cystitis/bladder pain syndrome | Phase 2 Data readout | |
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome with colon-in-continuity , Short bowel syndrome | Phase 2 Update | |
CNP-104 Details Autoimmune disease, Primary biliary cholangitis, Liver disease | Phase 2a Data readout | |
Linaclotide Details Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation | Failed Discontinued |